Monocyte activation in congestive heart failure due to coronary artery disease and idiopathic dilated cardiomyopathy

International Journal of Cardiology

Volumn 63, Issue 3, 1998, Pages 237-244

  Vonhof, S ^a   Brost, B ^a   Stille Siegener, M ^a   Grumbach, I M ^a   Kreuzer, H ^a   Figulla, H R ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

Cytokines; Heart failure; Monocyte activation; Tumor necrosis factor

Indexed keywords

CYTOKINE; ESCHERICHIA COLI LIPOPOLYSACCHARIDE; INTERLEUKIN 1BETA; NEOPTERIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA RECEPTOR;

ACUTE HEART FAILURE; ADULT; AGED; ARTICLE; CHRONIC DISEASE; CLINICAL ARTICLE; CONGESTIVE CARDIOMYOPATHY; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; FEMALE; HUMAN; LEUKOCYTE ACTIVATION; MALE; MONOCYTE; PRIORITY JOURNAL;

BIOLOGICAL MARKERS; CARDIOMYOPATHY, DILATED; CORONARY DISEASE; HEART FAILURE, CONGESTIVE; HEMODYNAMIC PROCESSES; HUMANS; INTERLEUKIN-1; MIDDLE AGED; MONOCYTES; RECEPTORS, TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0032574180     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-5273(97)00332-X     Document Type: Article

References (23)

1. Beutler B., Cerami A. Cachectin: More than a tumour necrosis factor. N Engl J Med. 316:1987;379-385.
2. Gulick T., Chung M.K., Pieper S.J., Lange L.G., Schreiner G.F. Interleukin 1 and tumor necrosis factor inhibit cardiac myocyte β-adrenergic responsiveness. Proc Natl Acad Sci USA. 86:1989;6753-6757.
3. Bristow M.R., Hershberger R.E., Port J.D.et al. Beta-adrenergic pathways in nonfailing and failing human ventricular myocardium. Circulation. 82(Suppl. I):1990;12-25.
4. Insel P.A. Adrenergic receptors - Evolving concepts and clinical implications. N Engl J Med. 334:1996;580-581.
5. Finkel M.S., Oddis C.V., Jacob T.D., Watkins S.C., Hattler B.G., Simmons R.L. Negative inotropic effects of cytokines are mediated by nitric oxide. Science. 257:1992;387-389.
6. Levine B., Kalman J., Mayer L., Fillit H.M., Packer M. Elevated circulating levels of tumor necrosis factor in severe chronic cardiac failure. N Engl J Med. 323:1990;236-241.
7. Matsumori A., Shioi T., Yamada T., Matsui S., Sasayama S. Vesnarinone, a new inotropic agent inhibits cytokine production by stimulated human blood from patients with heart failure. Circulation. 89:1994;955-958.
8. Marriott J.B., Goldman J.H., Keeling P.J., Baig M.K., Dalgleish A.G., McKenna W.J. Abnormal cytokine profiles in patients with idiopathic dilated cardiomyopathy and their asymptomatic relatives. Heart. 55:1996;419-423.
9. Olsen EGJ. Macro- and micropathology of dilated cardiomyopathy. In: Figulla HR, Kandolf R, McManus B, editors. Idiopathic dilated cardiomyopathy. Cellular and molecular mechanisms, clinical consequences. Berlin Heidelberg: Springer, 1993:81-7.
10. DeForge L.E., Remick D.G. Kinetics of, IL-6, and IL-8 Gene Expression in lipopolysaccharide-stimulated human whole blood. Biochem Biophys Res Comm. 174:1991;18-24.
11. Tatzber F., Rabl H., Koriska K.et al. Elevated serum neopterin levels in atherosclerosis. Atherosclerosis. 89:1991;203-208.
12. Hönlinger M., Fuchs D., Hausen A.et al. Determination of serum neopterin to increase the safety of donated blood for transfusion. Dtsch Med Wschr. 114:1989;172-176.
13. Stille-Siegener M., Heim A., Figulla H.R. Subclassification of dilated cardiomyopathy and interferon treatment. Eur Heart J. 16(suppl. O):1995;147-149.
14. Caforio A.L.P., Steward J.T., McKenna W.J. Idiopathic dilated cardiomyopathy. Br Med J. 300:1990;890-891.
15. Limas C.J., Goldenberg I.F., Limas C. Soluble interleukin-2 receptor levels in patients with dilated cardiomyopathy. Circulation. 91:1995;631-634.
16. McMurray J., Abdullah I., Dargie H.J., Shapiro D. Increased concentrations of tumour necrosis factor in 'cachektic' patients with severe chronic heart failure. Br Heart J. 66:1991;356-368.
17. Dutka D.P., Elborn J.S., Delamere F., Shale D.J., Morris G.K. Tumour necrosis factor α in severe congestive cardiac failure. Br Heart J. 70:1993;141-143.
18. Lane J.R., Neumann D.A., Lafond-Walker A., Herskowitz A., Rose N.R. Interleukin 1 or tumor necrosis factor promote coxsackie B3-induced myocarditis in resistant B10. A mice. J Exp Med. 175:1992;1123-1129.
19. Maisch B, Bauer E, Drude L, Herzum M, Hufnagel G, Schönian U, Pankuweit S. Are anti-cardiac antibodies in dilated cardiomyopathy 'natural' antibodies? In: Figulla HR, Kandolf R, McManus B, editors. Idiopathic dilated cardiomyopathy. Cellular and molecular mechanisms, clinical consequences. Berlin, Heidelberg: Springer, 1993:335-50.
20. Anker S.D., Egerer K.R., Volk H.D.et al. Elevated soluble CD14 receptors and altered cytokines in chronic heart failure. Am J Cardiol. 79:1997;1426-1430.
21. Matsumori A., Yamada T., Suzuki H., Matoba Y., Sasayama S. Increased circulating cytokines in patients with myocarditis and cardiomyopathy. Br Heart J. 72:1994;561-566.
22. Fuchs D., Weiss G., Reibnegger G., Wachter H. The role of neopterin as a monitor of cellular activation in transplantation, inflammatory, infectious, and malignant diseases. Crit Rev Clin Lab Sci. 29:1992;307-341.
23. Huber C., Batchelor J.R., Fuchs D.et al. Immune response-associated production of neopterin. Release from macrophages primarily under control of interferon gamma. J Exp Med. 160:1984;310-316.